University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
NCT Number: NCT01068847
This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the participant's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each participant will receive 2-4 of the listed interventions.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Little Rock, Arkansas, 72205, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
Other names: Cycloserine: Seromycin, Naloxone: Narcan, Nifedipine: Adalat, Procardia, Placebo, Saline, Tizanidine: Zanaflex, Verapamil: Veralan
Time frame: Every Session
Time frame: Every Session
Time frame: Every session
Time frame: Test Sessions
University of Arkansas
Other
Acronym: OMDD3
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04003948
Behavior, Behavior, Addictive
Reus, Tarragona, Spain
View Trial DetailsNCT02396979
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
View Trial DetailsNCT01843023
Chemically-Induced Disorders, Drug Dependence
Baltimore, Maryland, United States
View Trial DetailsNCT03583138
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Washington D.C., District of Columbia, United States
View Trial Details